PMID: 8950881Dec 7, 1996Paper

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

Lancet
J J EronT Twaddell

Abstract

Most individuals infected with HIV-1 show disease progression despite both cellular and humoral immune responses. We investigated whether immunisation of patients who had symptomless HIV-1 infection with an envelope subcomponent vaccine (MNrgp120) to augment immune response can slow progression of HIV-1 disease. In a randomised, double-blind, placebo-controlled trial, carried out in university infectious disease clinics and community infectious disease practices, we enrolled 573 HIV-infected patients with CD4 counts above 600 cells/microL (0.6 x 10(9)/L). Patients received 600 micrograms vaccine or placebo by intramuscular injection monthly for 6 months then every alternate month throughout the study. The primary endpoint was the rate of decline in CD4 count; secondary endpoints were HIV-1 RNA concentrations in plasma and minor clinical events associated with HIV. Analysis was by intention to treat. At baseline, the study participants had a mean CD4 count of 775 cells/microL (SD 172) and 89% of participants had detectable HIV RNA (> 200 copies/mL). These RNA-positive individuals had a median viral load of 9250 copies/mL (IQR 2670-26960). Analysis after 15 months of follow-up of the 568 subjects who had at least one CD4 count do...Continue Reading

References

Sep 1, 1973·Journal of Chronic Diseases·J J Schlesselman
Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·E BarkerJ A Levy
Jan 26, 1995·The New England Journal of Medicine·G PantaleoL K Schrager
Apr 15, 1995·Annals of Internal Medicine·J W MellorsP Gupta
May 28, 1993·Science·J SalkG M Shearer

❮ Previous
Next ❯

Citations

Jul 1, 1997·Journal of Biomedical Science·R.B. MossF.C. Jensen
Aug 10, 2000·Vaccine·A D HorneK L Goldenthal
Dec 12, 2001·Vaccine·B S Peters
Sep 21, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·S L Pett, S Emery
May 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I Sereti, H C Lane
Feb 19, 1998·AIDS·A C LeanderssonB Wahren
Aug 1, 1997·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·S K KunduT C Merigan
Dec 22, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J S LambertG Smith
Jan 27, 2011·Drug Design, Development and Therapy·Lena J Gamble, Qiana L Matthews
Jan 1, 2007·Current Opinion in HIV and AIDS·Michael M LedermanBenigno Rodriguez
Jan 1, 2006·Current Opinion in HIV and AIDS·Sonya L Heath, J Michael Kilby
May 1, 2007·European Journal of Pain : EJP·Corinne G JolivaltNigel A Calcutt
Dec 1, 2001·Expert Opinion on Biological Therapy·R W RossJ A Tavel
Jun 12, 2002·Medical Hypotheses·R Torensma, C G Figdor
May 29, 2012·Human Vaccines & Immunotherapeutics·Felipe GarcíaTeresa Gallart
Apr 26, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·R B MossD J Carlo
Sep 22, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·L A PintoV Blazevic
Jun 11, 1998·Journal of Pharmaceutical Sciences·G A BrazeauP Gupta
Jan 31, 2002·HIV Clinical Trials·Vichai Jirathitikal, Aldar S Bourinbaiar
Apr 23, 2017·Expert Review of Vaccines·Lorna LealFelipe García
May 22, 2003·Dermatologic Clinics·Mathijs H BrentjensStephen K Tyring
Jan 6, 2001·Antiviral Chemistry & Chemotherapy·B S Peters
May 8, 2021·Frontiers in Pharmacology·Huan-Jun LuZhi-Jun Zhang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.